Skip to content
Back to explorer
Printable monograph

RAS(ON) multi-selective inhibitor

Daraxonrasib

Rasonque · DARX

RAS(ON) multi-selective inhibitor · approved 2026 · 7 citations

Up to date· through 2026
Deeply sourced7/9 · 6 signals
  • Met: 7 citations
  • Not met: 12+ references
  • Met: Accrued over 10+ years (span: 16y)
  • Met: Beyond single case reports
  • Met: High-impact journal
  • Met: Landmark reference
  • Met: Current through 2026
  • Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

The first RAS(ON) inhibitor, which blocks mutant and wild-type RAS alike. Its kidney story is mostly the gut's - creatinine rose in 24% against 9% on chemotherapy, beside 67% diarrhea - with one renal-limited thrombotic microangiopathy in the label.

ModerateRAS(ON) multi-selective inhibitor
Metastatic pancreatic adenocarcinoma in adults who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy (RASolute 302)Studied in previously treated RAS-mutant non-small-cell lung cancer (RMC-6236-001, phase 1-2)

Kidney summary

Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.

Renal dosing
Not in the atlas's table of label-specified renal dose changes; the Dosing section has the full entry.
Hemodialysis
Not removed by hemodialysis
Not studied below CLcr 30 or on dialysis; ~98% protein-bound with an apparent volume of distribution of 1,060 L and ~1% of a dose in urine (FDA label), so intermittent hemodialysis would remove very little. No post-dialysis dose is defined; dose changes are for CYP3A/P-gp interactions, not kidney function.
The atlas summary. Full prose in the Dialyzability section.
FDA boxed warning
No FDA label excerpt in the atlas.
§01

Signature kidney injury

Representative incidence24%

Daraxonrasib carries a renal laboratory signal against an active comparator, and the FDA label is the only source for it. In RASolute 302's laboratory table, creatinine increased from baseline in 24% of patients on daraxonrasib (grade 3-4 0.8%) against 9% on physician's-choice chemotherapy (grade 3-4 0%), with denominators of 234-237 and 207-208. Electrolyte losses ran alongside it: sodium decreased in 36% (grade 3-4 6%) against 30%, and magnesium in 34% against 22%, while potassium decreased less often than on chemotherapy (20% against 33%). Among clinically important adverse reactions under 10%, the label lists renal-limited thrombotic microangiopathy in 0.4% of the 241 patients treated - one patient. Diarrhea (67%, grade 3-4 7%) and vomiting (42%) were more frequent than on chemotherapy (44% and 25%), and diarrhea was the commonest serious adverse reaction (3.7%). Neither published RASolute 302 abstract reports a renal row.Source: Creatinine increased 24% all-grade / 0.8% grade 3-4 on daraxonrasib (n=234-237) versus 9% / 0% on chemotherapy (n=207-208); renal-limited TMA 0.4% (N=241) - FDA label, RASolute 302

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

  1. Prerenal / Hemodynamic AKI#1 · Signaturequalitative — no citable incidence · drug-level figure in §01

    Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

  2. Electrolyte DisturbanceSecondaryqualitative — no citable incidence

    Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).

  3. Thrombotic MicroangiopathySecondaryqualitative — no citable incidence

    Endothelial injury with microvascular thrombi, hemolysis and thrombocytopenia — gemcitabine, mitomycin C, anti-VEGF.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

24%incidence

Representative incidence

SeverityModerate
ReversibilityReversible
Evidence7 citations
Nephron map

Functional / pre-renal — reduced perfusion upstream of the nephron; no single structural segment is injured.

Prerenal / Hemodynamic AKI: functional / pre-renal, no single structural segment injured.

Glomerulus — not involved
Vasculature / Endothelium — not involved
Distal Tubule / Collecting Duct — not involved

Prerenal / Hemodynamic AKI

Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

§03

Kidney injury

Mechanism of kidney injury

The mechanism of the creatinine excess is not established. The documented route is volume and electrolyte loss: diarrhea began at a median of 3 days in the pooled pancreatic population and occurred in 67% of the RASolute 302 arm, with vomiting in 42% and decreased appetite in 24%, so prerenal physiology is the expected explanation for most rises. Whether daraxonrasib also blocks tubular creatinine secretion, as several kinase and KRAS G12C inhibitors do, is not answerable from the label, which reports no in vitro OCT2 or MATE data. The kidney is not its clearance route: about 93% of a radiolabelled dose is recovered in feces and about 1% in urine. The single renal-limited thrombotic microangiopathy is named in the label without a mechanism. Daraxonrasib blocks wild-type as well as mutant RAS, and its on-target toxicities fall on normal tissues, but whether glomerular endothelium is one of them is unknown; the case should not be read as evidence for a class effect.

Clinical presentation

Most often a creatinine rise in the first weeks that tracks diarrhea, vomiting and poor intake, with low sodium or magnesium, a concentrated urine and a bland sediment, and that improves with volume repletion and a dose interruption. Hypoalbuminemia is common on the drug (albumin decreased in 71% against 51%) and edema in 25%, so intravascular depletion can coexist with peripheral edema. The rarer presentation to keep in mind is thrombotic microangiopathy: a creatinine rise with new hypertension, proteinuria or hematuria, and possibly no peripheral hemolysis, since the label's case was renal-limited.

Management

Treat a creatinine rise as prerenal first: assess volume, give fluids and electrolytes, treat the diarrhea, and withhold the drug for grade 3 diarrhea, nausea or vomiting (and consider it for grade 2 diarrhea), resuming at the next lower dose once recovered to grade 1. A rise that does not respond to volume, or comes with new hypertension, proteinuria, hematuria, a falling platelet count or schistocytes, needs a workup for thrombotic microangiopathy - urinalysis with quantified protein, blood film, LDH, haptoglobin and platelet count - and consider a kidney biopsy if hemolysis is absent but the suspicion stands, since the label's case was renal-limited. Under the label's 'other adverse reactions' rule, a grade 3 event means withholding until grade 1 or baseline and resuming at the next lower dose; grade 4 means permanent discontinuation. Dose levels are 300, 200 and 150 mg; a patient who cannot tolerate 150 mg stops the drug.Lesion-level management framework

Risk factors

  • Diarrhea, vomiting or stomatitis limiting oral intake - the documented route to prerenal azotemia, hyponatremia and hypomagnesemia
  • Concomitant diuretics, ACE inhibitors, ARBs or NSAIDs during GI losses
  • Strong CYP3A inhibitors with P-gp inhibition (itraconazole raised AUC 5.1-fold) or other interacting drugs, since higher exposure brought more diarrhea and grade 3 or higher reactions
  • Creatinine clearance below 30 mL/min - the label states the effect on daraxonrasib exposure there is unknown
  • Systemic cyclosporine, which binds the same cyclophilin A the drug depends on and is to be avoided - relevant to kidney transplant recipients

Prevention

  • Start antidiarrheal treatment at the first loose stool and replace fluid and electrolytes early, since diarrhea typically begins within days
  • Hold diuretics, ACE inhibitors, ARBs and NSAIDs during significant diarrhea or vomiting
  • Follow the label's dose reductions for CYP3A and P-gp inhibitors, and avoid strong CYP3A inhibitors that also inhibit P-gp, so exposure-driven GI toxicity is not added
  • Avoid systemic cyclosporine; in a transplant recipient, settle the immunosuppression question with the transplant team before the first dose
Anticancer mechanism· how it treats cancer

Oral RAS(ON) multi-selective tri-complex inhibitor. Daraxonrasib binds the intracellular chaperone cyclophilin A, and the binary complex then binds the active, GTP-bound state of RAS, blocking its interaction with downstream effectors and promoting GTP hydrolysis to the inactive state. It inhibits wild-type and mutant KRAS, NRAS and HRAS, which is why its toxicities resemble broad RAS-pathway blockade (skin, mucosa, gut) rather than a single-mutant inhibitor's. Given as 300 mg orally once daily, with dose reductions to 200 mg and then 150 mg for adverse reactions.

§04

Clinical depth

Renal dose adjustment

No renal dose adjustment is recommended or defined. The label has no renal-impairment subsection; its pharmacokinetics section reports no clinically significant differences at creatinine clearance 30 to 89 mL/min, and states that the effect below 30 mL/min is unknown. The dose changes the label does make are for drug interactions: 150 mg once daily with a strong CYP3A inhibitor lacking P-gp inhibition or with a P-gp inhibitor, 100 mg with a moderate CYP3A inhibitor that inhibits P-gp, 200 mg with a moderate CYP3A inhibitor that does not, and 400 mg with an unavoidable strong or a moderate CYP3A inducer. Strong CYP3A inhibitors with P-gp inhibition, and systemic cyclosporine, are to be avoided.

Dialyzability & ESKD dosing

Not studied, and unlikely to be meaningfully removed. The label gives about 98% plasma protein binding, an apparent volume of distribution of 1,060 L and a 9.2-hour half-life, and about 1% of a dose appears in urine, so intermittent hemodialysis would reach very little of the drug. No post-dialysis timing or supplemental dose is defined, and because severe impairment and kidney failure were not characterized, use on dialysis rests on that inference rather than on measured data. Peritoneal dialysis and CRRT are not characterized.

Differential diagnosis

Prerenal azotemia from diarrhea, vomiting and poor intake is the leading explanation, and the electrolyte pattern (low sodium and magnesium) usually comes with it. Then consider an unknown creatinine-secretion component - the label neither shows nor excludes one, so a cystatin C-based estimate is reasonable before acting on a creatinine rise that has no other cause. Keep thrombotic microangiopathy on the list when creatinine rises with hypertension, proteinuria or hematuria, remembering that the label's case was renal-limited and a normal blood film does not exclude it. In metastatic pancreatic cancer also consider obstruction (ureteric compression from nodal or peritoneal disease), sepsis (2.9% serious), contrast and nephrotoxic co-medications. Prior chemotherapy is part of the background: gemcitabine carries its own thrombotic microangiopathy risk (see its profile) and should be weighed in a patient who received it recently.

Monitoring

  • Serum creatinine, sodium, magnesium, potassium and calcium at baseline and through the first weeks, and with any diarrhea or vomiting
  • Volume status, oral intake and stool frequency, starting in the first week
  • Blood pressure and urinalysis with quantified protein when creatinine rises without an obvious prerenal cause, to screen for thrombotic microangiopathy
  • Platelet count, LDH and blood film if thrombotic microangiopathy is suspected
  • The full medication list for CYP3A and P-gp inhibitors or inducers at every change, since they move the dose

Key trials & series

  • RASolute 302 (NCT06625320; phase 3, open-label, randomized) - 500 patients with previously treated metastatic pancreatic adenocarcinoma received daraxonrasib 300 mg daily or physician's-choice chemotherapy (mFOLFIRINOX, gemcitabine with nab-paclitaxel, FOLFOX, or nal-IRI with 5-FU/leucovorin). Median overall survival 13.2 versus 6.7 months in the overall population (hazard ratio 0.40); grade 3 or higher adverse events 61.8% versus 69.6%; treatment-related discontinuation 1.2% versus 11.2% (O'Reilly, N Engl J Med 2026). The abstract reports no renal row; the label's creatinine, electrolyte and thrombotic microangiopathy figures come from this trial's 241- and 214-patient safety arms.
  • RMC-6236-001 pancreatic cohort (NCT05379985; phase 1-2; Wolpin, N Engl J Med 2026) - 168 patients at doses up to 300 mg, with treatment-related events in 96% and grade 3 or higher in 30%; rash, diarrhea, nausea, stomatitis, vomiting and fatigue in at least 10%. Established the 300 mg phase 3 dose. No renal endpoint in the abstract.
  • RMC-6236-001 lung cohort (Arbour, N Engl J Med 2026) - 136 patients with previously treated RAS-mutant NSCLC; grade 3 or higher adverse events in 54%, with diarrhea in 9%. No renal endpoint in the abstract.

Clinical pearls

  • Creatinine rose in 24% on daraxonrasib against 9% on chemotherapy - an excess the label reports and does not explain. Diarrhea in 67% is the documented route; a secretion artifact is neither shown nor excluded.
  • The label names one renal-limited thrombotic microangiopathy in 241 patients. Renal-limited means the blood film can be normal, so a biopsy may be what finds it.
  • Daraxonrasib needs cyclophilin A to work, and so does cyclosporine. The label says to avoid systemic cyclosporine - ask about a transplant before the first dose.
  • Daraxonrasib inhibits P-gp. Predicted free dabigatran exposure rises about 2-fold, in a renally cleared anticoagulant whose own exposure already climbs with falling kidney function - the label separates the two by at least 4 hours.
  • No renal dose change is defined, but nothing is known below creatinine clearance 30. The drug's own dose moves for CYP3A and P-gp interactions far more often than it would for the kidney.
§05

References

7 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

7 references · 2010–2026 · 6 since 2024
402010: 1 citation2024: 1 citation2025: 1 citation2026: 4 citations201020202026

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

  1. 1.LandmarkDaraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.O'Reilly EM et al. · N Engl J Med · 2026 · PMID 42223072The registrational RASolute 302 phase 3 trial: 500 patients randomized to daraxonrasib or chemotherapy; median overall survival 13.2 versus 6.7 months in the overall population (hazard ratio 0.40); grade 3 or higher adverse events 61.8% versus 69.6%; treatment-related discontinuation 1.2% versus 11.2%. The abstract reports no renal endpoint - the label's renal laboratory and thrombotic microangiopathy figures come from this trial's safety arms.
  2. 2.LandmarkDaraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.Wolpin BM et al. · N Engl J Med · 2026 · PMID 42090791Phase 1-2 RMC-6236-001 in 168 patients with previously treated RAS-mutated pancreatic cancer at doses of 10 to 400 mg: treatment-related events in 96%, grade 3 or higher in 30%, led by rash, diarrhea, nausea, stomatitis and vomiting; 300 mg selected for phase 3. No renal endpoint.
  3. 3.Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.Arbour KC et al. · N Engl J Med · 2026 · PMID 42685317Phase 1-2 lung cohort of 136 patients: adverse events of grade 3 or higher in 54%, with diarrhea in 9% - the same gastrointestinal toxicity profile outside pancreatic cancer. No renal endpoint.
  4. 4.Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers.Cregg J et al. · J Med Chem · 2025 · PMID 40056080The discovery paper for the tri-complex mechanism: daraxonrasib, cyclophilin A and RAS(ON) form a complex that blocks effector binding, with deliberate activity against both mutant and wild-type RAS isoforms. The basis for the cyclophilin A dependence behind the label's cyclosporine warning.
  5. 5.Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.Jiang J et al. · Cancer Discov · 2024 · PMID 38593348Preclinical and early clinical evaluation of concurrent mutant and wild-type RAS-GTP inhibition, including the PK/PD modelling that pointed to the 300 mg dose. Frames why the toxicities fall on normal RAS-dependent tissues.
  6. 6.Daraxonrasib (RMC-6236) pharmacokinetics: impact of transporters and drug-metabolizing enzymes on a first-in-class pan-RAS molecular glue.Arguedas D et al. · Pharmacol Res · 2026 · PMID 42107507Mouse and in vitro work showing ABCB1 (P-gp) efflux, OATP1A/1B uptake and CYP3A4 as the determinants of daraxonrasib exposure - the transporter and enzyme basis for the label's interaction-driven dose changes. It does not address renal transporters.
  7. 7.Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.Stangier J et al. · Clin Pharmacokinet · 2010 · PMID 20214409Dabigatran exposure rose 1.5-, 3.2- and 6.3-fold with mild, moderate and severe renal impairment. The reason the label's predicted 2-fold rise in free dabigatran with daraxonrasib, a P-gp inhibitor, matters more in a patient with reduced kidney function.

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 10 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

  • Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.
FAERS outcomes & reporting trend· 0 of 10 reports w/ death · 6 w/ hospitalization

10 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.

0 of 10

Reported with a death outcome

too few reports to express as a share

6 of 10

Reported with hospitalization

too few reports to express as a share

Reports per year

  • 2015: 0 reports
  • 2016: 0 reports
  • 2017: 0 reports
  • 2018: 0 reports
  • 2019: 0 reports
  • 2020: 0 reports
  • 2021: 0 reports
  • 2022: 0 reports
  • 2023: 0 reports
  • 2024: 0 reports
  • 2025: 0 reports
  • 2026: 10 reports

Reports received per year, 2015–2026 · most recent year is partial.

FAERS adverse-event signal — all organ systems· 9 systems · 10 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.

Renal & urinary
Renal Disorder1
Gastrointestinal
Diarrhoea4Nausea4Vomiting4Stomatitis2Abdominal Pain Upper1
Metabolic & electrolyte
Dehydration4
Skin
Rash2Oral Mucosal Erythema1Skin Laceration1
Vascular
Blood Pressure Decreased1Hypotension1Skin Haemorrhage1
General / constitutional
Fatigue1Malaise1Pain1
Nervous system
Dysgeusia1Neuropathy Peripheral1
Cardiac
Cardiac Disorder1
Respiratory
Dyspnoea1
Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Daraxonrasib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.
Phenotype-similar agents· the numbered markers on the map above

Doxifluridine

Furtulon · Antimetabolite (oral 5-FU prodrug)

Profile

5'-DFUR prodrug; class-level TMA risk plus a real renal-clearance component warranting caution in renal impairment.

TMALYTEPRE
Moderate#1 · 86% phenotype match

Carmofur (HCFU)

Mifurol · Antimetabolite (oral 5-FU prodrug)

Profile

Lipophilic oral 5-FU prodrug (Japan); class-level renal risk; hallmark toxicity is leukoencephalopathy not nephropathy.

TMALYTEPRE
Moderate#2 · 85% phenotype match

Tegafur-uracil (UFT)

UFT · Antimetabolite (oral 5-FU prodrug)

Profile

Oral tegafur+uracil; rare fluoropyrimidine-class TMA/HUS (often with mitomycin C), otherwise kidney-sparing.

TMALYTEPRE
Severe#3 · 80% phenotype match

Moxetumomab pasudotox

Lumoxiti · Immunotoxin (anti-CD22 PE38)

Profile

Boxed warning for capillary-leak syndrome and hemolytic-uremic syndrome / TMA.

TMAPRE
Severe#4 · 78% phenotype match

Ziftomenib

Komzifti · Menin inhibitor

Profile

2025 NPM1-mutated AML menin inhibitor; differentiation syndrome and tumor lysis.

PRELYTE
Moderate#5 · 72% phenotype match

Afamitresgene autoleucel (Afami-cel)

Tecelra · MAGE-A4 TCR-T cell therapy

Profile

First TCR-T cell therapy for a solid tumor; CRS-associated hemodynamic AKI.

PRELYTE
Moderate#6 · 72% phenotype match
Compare Daraxonrasib with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.